Timberlyne Therapeutics vs Stipple Bio
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $180M Series A (Jan 2025). CM313 achieved 95% response rate in treatment-refractory ITP in NEJM-published data. Multi-indication 2026 pipeline. CD38 target with differentiated cytotoxicity.
About
Timberlyne Therapeutics launched in January 2025 with $180 million in Series A financing from Abingworth, Bain Capital Life Sciences, and Venrock, developing CM313 — an anti-CD38 monoclonal antibody with differentiated complement-dependent cytotoxicity properties. CM313 achieved a 95% response rate in treatment-refractory immune thrombocytopenia (ITP) in data published in the New England Journal of Medicine in 2025 — a 95% response rate in refractory patients is exceptional in autoimmune disease.
Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led by RA Capital and a16z Bio; Pointillist platform identifies novel tumor-specific epitopes for antibody-drug conjugates beyond existing ADC targets.
About
Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andreessen Horowitz Bio+Health, and Nextech, with additional participation from GV and Emerson Collective — a top-tier syndicate that signals strong scientific conviction in the platform.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.